Yeast on the Final Frontier
A team led by Imperial College London has launched a miniature lab into Earth orbit to test the production of edible proteins in space with the help of yeast-based biotech.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1224 entries already.
Entries by Thomas Gabrielczyk
betaSense GmbH identifies new diagnostic biomarker for Parkinson’s
/in News/by Thomas GabrielczykA new biomarker for Parkinson’s disease makes it possible to recognise and treat the hereditary dopamine deficiency before the mid-brain is damaged, reports University Bochum spin-out betaSense GmbH.
Oryzon cashes in €30m
/in News/by Thomas GabrielczykBarcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Cytovation ASA bags additional US$6m to drive Phase II study
/in News/by Thomas GabrielczykCytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
KKR makes US$1.22bn tender for Swedish Biotage AB
/in News/by Thomas GabrielczykRWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.
Boehringer Ingelheim inks deal with Tessallate Bio
/in News/by Thomas GabrielczykBoehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Roche and Novartis react to US tariffs
/in News/by Thomas GabrielczykDespite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
Whey Waste Finds New Life as Protein
/in News/by Thomas GabrielczykFrench dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.
AMT-130 gets FDA breakthrough therapy designation
/in News/by Thomas GabrielczykAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Netherlands Sets Sights on Global Biotech Leadership
/in News/by Thomas GabrielczykThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding.